DYNLRB1 and cancer: Herein, the bLP-mediated TECA strategy efficiently disrupt the TSM barriers and exceedingly promote the accessibility of second M-bLP to cancer cells in tumor, and ultimately produced prominent therapeutic outcomes on tumor relapse and metastasis, which was superior to the counterpart liposomal formulations.